Erin joined Novo Holdings A/S in January 2020 as a Senior Associate in Principal Investments. She participates in deal sourcing and execution, as well as in managing the existing portfolio.
Prior to joining, Erin worked in Corporate Strategy at Novozymes, and before that in management consulting for Boston Consulting Group in Copenhagen. During this time, she focused on commercial due diligence for Life Science investors, as well as strategic projects for Diagnostics, MedTech and Pharma companies. Erin additionally brings over 10 years of scientific research experience in drug delivery and tissue engineering topics related to cardiovascular diseases and cancer immunotherapies.
Erin holds a PhD and MS in Bioengineering from Harvard University, and a BS in Bioengineering from the University of Washington, in Seattle.